Literature DB >> 8910163

Myocardial stunning, hibernation, and ischemic preconditioning.

M B Vroom1, H B van Wezel.   

Abstract

From the present review, it may be concluded that myocardial ischemia results in far more complicated syndromes than previously realized. Although not all aspects of the issues discussed in this review are currently a clinical reality in the daily practice of cardiovascular anesthesiologists, the understanding and application of these concepts are growing rapidly. Indications for revascularization procedures will be adjusted in patients with evidence of hibernating myocardium. In the future, postoperative myocardial dysfunction may be diminished by the prevention of myocardial stunning, for instance by altering the composition of the cardioplegic solution and other interventions. Finally, additional advances may involve reduction of the extent of perioperative myocardial infarctions by application of ischemic preconditioning.

Entities:  

Mesh:

Year:  1996        PMID: 8910163     DOI: 10.1016/S1053-0770(96)80209-6

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  2 in total

1.  Potentially neuroprotective gene modulation in an in vitro model of mild traumatic brain injury.

Authors:  Valentina Di Pietro; Angela M Amorini; Barbara Tavazzi; David A Hovda; Stefano Signoretti; Christopher C Giza; Giacomo Lazzarino; Roberto Vagnozzi; Giuseppe Lazzarino; Antonio Belli
Journal:  Mol Cell Biochem       Date:  2012-12-15       Impact factor: 3.396

2.  Preconditioning with levosimendan reduces postoperative low cardiac output in moderate-severe systolic dysfunction patients who will undergo elective coronary artery bypass graft surgery: a cost-effective strategy.

Authors:  Juan José Jiménez-Rivera; Andrea Álvarez-Castillo; Jorge Ferrer-Rodríguez; José Luis Iribarren-Sarrías; Martín Jesús García-González; Pablo Jorge-Pérez; Juan Lacalzada-Almeida; Rosalía Pérez-Hernández; Javier Montoto-López; Rafael Martínez-Sanz
Journal:  J Cardiothorac Surg       Date:  2020-05-24       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.